A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2012

At a glance

  • Drugs CX 157 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2010 This trial will be supported by the proceeds of a recently completed $13 million Series C financing, according to a CeNeRx BioPharma media release.
    • 05 Jul 2010 Status changed from recruiting to completed as results have been reported.
    • 10 Jun 2010 Results were presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top